Advertisement

New HPV Test Approved — Physician’s First Watch

Medical News |
April 21, 2011

New HPV Test Approved

The FDA has approved a new diagnostic test (cobas 4800) for the most carcinogenic strains of human papillomavirus (i.e., HPV types 16 and 18).

The cobas 4800 test detects 14 high-risk HPV genotypes, including types 16 and 18, which are found in 70% of cervical cancer cases, according to the manufacturer.

Approval was based on data from a trial of some 47,000 women who were screened for cervical cancer using both a Pap test and the new HPV test. About 1 in 10 women aged 30 and older who tested positive for HPV types 16 and/or 18 by the cobas test had cervical precancer even though their Pap test results were normal.

Reader Comments (2)

juan carlos castillo marin ruiz Resident, Obstetrics/Gynecology

podrá parar el abuso de la colposcopía y de sus sobremanejos.y de tal forma el fraude que significa el sobretratamiento.

Moawia Hummeida Physician, Obstetrics/Gynecology, Khartoum, Sudan

What is the difference of this new product and the HPV DNA Fast or Care test developed by PATH and tested in China?
Is it available as a cervical cell test only? Or blood test and what about the cost?

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement